| # | Title | Journal | Year | Citations |
|---|
| 1 | Tumor Biologic Factors and Breast Cancer Prognosis Among White, Hispanic, and Black Women in the United States | Journal of the National Cancer Institute | 1994 | 386 |
| 2 | Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. | Journal of Clinical Investigation | 1989 | 282 |
| 3 | Flow cytometry, cellular DNA content, and prognosis in human malignancy. | Journal of Clinical Oncology | 1987 | 258 |
| 4 | MINIREVIEW: Estrogen Receptor Variants in Clinical Breast Cancer | Molecular Endocrinology | 1991 | 250 |
| 5 | Investigation of taxol as a potential radiation sensitizer | Cancer | 1993 | 216 |
| 6 | Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients | Cancer | 1993 | 188 |
| 7 | Consensus review of the clinical utility of dna cytometry in carcinoma of the breast | Cytometry | 1993 | 171 |
| 8 | Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells | Journal of Biological Chemistry | 1998 | 147 |
| 9 | Bid-induced release of AIF from mitochondria causes immediate neuronal cell death | Cell Death and Differentiation | 2008 | 131 |
| 10 | Telomerase Activity and Survival of Patients With Node-Positive Breast Cancer | Journal of the National Cancer Institute | 1997 | 129 |
| 11 | bcl-2 and apoptosis in lymph node positive breast carcinoma | Cancer | 1998 | 119 |
| 12 | Prognostic Factors and Therapeutic Decisions in Axillary Node-Negative Breast Cancer | Annual Review of Medicine | 1993 | 117 |
| 13 | Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3′-Kinase Inhibition | Molecular and Cellular Biology | 2000 | 113 |
| 14 | Estrogen receptor mutations in breast cancer | Journal of Cellular Biochemistry | 1993 | 109 |
| 15 | Prognostic significance of p53 gene alterations in node-negative breast cancer | Breast Cancer Research and Treatment | 1993 | 104 |
| 16 | Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status | Journal of Cellular Biochemistry | 1993 | 90 |
| 17 | Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer | Cancer Research | 1991 | 87 |
| 18 | Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis | Cancer Research | 1988 | 81 |
| 19 | p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer | Cancer Research | 1994 | 81 |
| 20 | Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells | Journal of Cellular Physiology | 1993 | 75 |
| 21 | A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma | Cancer | 1996 | 73 |
| 22 | Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells | Cancer Research | 2003 | 72 |
| 23 | A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma | | 1996 | 62 |
| 24 | Abnormal estrogen receptor in clinical breast cancer | Journal of Steroid Biochemistry and Molecular Biology | 1992 | 61 |
| 25 | The role and prognostic significance of p53 gene alterations in breast cancer | Breast Cancer Research and Treatment | 1993 | 45 |
| 26 | Sp1 is essential for estrogen receptor α gene transcription | Journal of Steroid Biochemistry and Molecular Biology | 2002 | 44 |
| 27 | Smad4-dependent TGF-β Signaling Suppresses RON Receptor Tyrosine Kinase-dependent Motility and Invasion of Pancreatic Cancer Cells | Journal of Biological Chemistry | 2008 | 44 |
| 28 | MODELS FOR EARLY CHEMOPREVENTION TRIALS IN BREAST CANCER | Hematology/Oncology Clinics of North America | 1998 | 43 |
| 29 | Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base | Cancer | 1993 | 42 |
| 30 | Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer | Cancer Research | 1997 | 39 |
| 31 | Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients | Cancer | 1993 | 35 |
| 32 | Downregulation of STAT3/NF‐κB potentiates gemcitabine activity in pancreatic cancer cells | Molecular Carcinogenesis | 2017 | 32 |
| 33 | A cDNA for the estradiol-regulated 24K protein: Control of mRNA levels in MCF-7 cells | Breast Cancer Research and Treatment | 1988 | 26 |
| 34 | Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500) | American Journal of Hematology | 2007 | 26 |
| 35 | A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma | Cancer | 1996 | 25 |
| 36 | Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast | Breast Cancer Research and Treatment | 1993 | 24 |
| 37 | Neural network analysis of DNA flow cytometry histograms | Cytometry | 1993 | 22 |
| 38 | Estrogen receptor mutagenesis and hormone resistance | Cancer | 1994 | 21 |
| 39 | Targeted gene therapy for breast cancer with truncated Bid | Cancer Gene Therapy | 2006 | 20 |
| 40 | 125I-ligand for progesterone receptor: 17α-(6'-iodohex-1'-ynyl)-19-nortestosterone | The Journal of Steroid Biochemistry | 1989 | 16 |
| 41 | An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor | Journal of Steroid Biochemistry and Molecular Biology | 1996 | 15 |
| 42 | The Current Status of Irinotecan (CPT-11) in the United States | Annals of the New York Academy of Sciences | 1996 | 15 |
| 43 | Rap1 reverses transcriptional repression of TGF-? type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1 | Journal of Cellular Physiology | 2003 | 12 |
| 44 | A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: A Southwest Oncology Group Study | Urologic Oncology: Seminars and Original Investigations | 2005 | 10 |
| 45 | Estrogen receptor variants in breast cancer | Cancer Treatment and Research | 1994 | 10 |
| 46 | A Practical View of Prognostic Factors for Staging, Adjuvant Treatment Planning, and as Baseline Studies for Possible Future Therapy | Hematology/Oncology Clinics of North America | 1994 | 9 |
| 47 | The importance of normal and abnormal oestrogen receptor in breast cancer | Cancer Surveys | 1992 | 9 |
| 48 | Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer. | Journal of Clinical Oncology | 1995 | 8 |
| 49 | Basic Pharmacokinetics and Pharmacodynamic Principles | Cancer Treatment and Research | 2001 | 6 |
| 50 | Abnormal oestrogen receptor in clinical breast cancer | European Journal of Cancer | 1992 | 5 |
